Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

Abstract

Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.